The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block Listing Application and Directors' Dealings

21 Jun 2016 10:47

RNS Number : 8202B
Premier Veterinary Group PLC
21 June 2016
 

 

 

 

EXERCISE OF OPTIONS AND WARRANTS

 

DIRECTOR'S DEALING

 

TOTAL VOTING RIGHTS

 

BLOCK LISTING APPLICATION

 

Exercise of options and warrants

 

London, 21 June 2016: Premier Veterinary Group plc (LSE: PVG) (the "Company") announces that it has received notices of exercise of options under the Company's Enterprise Management Incentive Share Option Plan (the "EMI Plan") from certain employees and a Director of the Company (the "Option Exercise") to subscribe for a total of 816,143 new ordinary shares of 10 pence each in the Company (the "New Ordinary Shares"). The exercise price of the options is 10.1 pence each.

 

In addition, the Company has received notice of exercise of warrants from WG Partners LLP to subscribe for 139,517 New Ordinary Shares at a price of 10.1 pence per share. Warrants over 279,034 ordinary shares of 10 pence each were granted to WG Partners LLP as part of the arrangements relating to the reverse acquisition by the Company of Premier Veterinary Group Limited (now PVG 2007 Limited) completed in February 2015. The balance of the warrants will vest and become exercisable with effect from 27 February 2017.

 

Application has been made to the London Stock Exchange for the admission of a total of 955,660 New Ordinary Shares to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities ("Admission"). Admission is expected to occur on or around 23 June 2016. The New Ordinary Shares will rank pari passu with the existing ordinary shares in the Company.

 

Directors' dealings

 

Included in the above total of 816,143 share options are 209,277 options which were exercised by Daniel Smith, a Director of the Company.

Following the exercise of these options, Daniel Smith owns 209,277 ordinary shares, representing approximately 1.4% of the Company's enlarged issued share capital. Mr Smith holds no further share options.

 

Total voting rights

 

Following Admission, the Company's enlarged issued share capital will comprise 14,907,433 ordinary shares. The Company does not hold any shares in treasury. The figure of 14,907,433 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 

Block Listing Application

The Company further announces that is has made a block listing application to the London Stock Exchange for the admission of up to 579,035 ordinary shares of 10 pence each to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities.

The block listing application relates to 579,035 shares, being the total number of shares that could be issued pursuant to the exercise of all options currently outstanding under the EMI Plan. If all the options were exercised, the shares that would be issued would represent approximately 3.88% of the enlarged issued share capital.

 

The application for the admission of these shares has been made in advance for ease of administration as all the outstanding options under the EMI Plan vested and became exercisable on 27 February 2016.

Shares issued pursuant to the exercise of options under the EMI Plan will rank pari passu with the existing ordinary shares of 10 pence each in the share capital of the Company.

It is expected that the block admission will become effective on 23 June 2016.

 

 

Enquiries:

 

Premier Veterinary Group plc

Sue Steven, Company Secretary +44 (0)117 370 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDMGZVLMKGVZG
Date   Source Headline
1st Mar 201310:50 amRNSForm 8.3 - [Ark Therapeutics]
26th Feb 20135:35 pmRNSHolding(s) in Company
26th Feb 20139:33 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:55 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:27 amRNSHolding(s) in Company
22nd Feb 20132:41 pmRNSHolding(s) in Company
21st Feb 20131:24 pmPRNForm 8.3 - Ark Therapeutics plc
21st Feb 201310:56 amRNSHolding(s) in Company
20th Feb 201312:54 pmPRNForm 8.3 - Ark Therapeutics plc
20th Feb 201312:11 pmRNSForm 8.3 - [Ark Therapeutics Group PLC]
19th Feb 20134:40 pmRNSSecond Price Monitoring Extn
19th Feb 20134:35 pmRNSPrice Monitoring Extension
15th Feb 201312:57 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Feb 201310:39 amPRNForm 8.3 - Ark Therapeutics Group plc
12th Feb 201312:25 pmRNSHolding(s) in Company
7th Feb 20133:05 pmRNSHolding(s) in Company
7th Feb 20131:41 pmPRNForm 8.3 - Ark Therapeutics Group
6th Feb 20134:43 pmRNSForm 8.3 - Ark Therapeutics
6th Feb 201311:18 amPRNForm 8.3 - Ark Therapeutics Group
6th Feb 201311:02 amRNSForm 8 (OPD)
5th Feb 20134:35 pmRNSPrice Monitoring Extension
5th Feb 20132:48 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Feb 20132:43 pmRNSForm 8.3 - Ark Therapeutics Group Plc
4th Feb 20131:10 pmRNSForm 8.3 - Ark Therapeutics
4th Feb 201310:11 amRNSForm 8.3 - [Ark Therapeutics]
1st Feb 20133:10 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Feb 20132:53 pmRNSForm 8.3 - Ark Therapeutics Amendment
1st Feb 201312:41 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 20133:42 pmRNSForm 8.3 - Ark Therapeutics Group PLC
31st Jan 20131:40 pmRNSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 20131:31 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 201312:02 pmRNSForm 8.3 - ARK Therapeutics plc
31st Jan 201311:51 amBUSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 201311:14 amPRNForm 8.3 - Ark Therapeutics Group
30th Jan 20134:03 pmRNSForm 8.3 - Ark Therapeutics Group Plc
30th Jan 20137:00 amRNSStrategic Review Update
24th Jan 20133:33 pmRNSHolding(s) in Company
21st Jan 20137:00 amRNSCompany Update
4th Dec 20123:40 pmRNSBlocklisting Six Monthly Return
30th Nov 20127:00 amRNSFrench Tax Credit for Research and Development
8th Nov 20127:00 amRNSInterim Management Statement
15th Oct 20127:00 amRNSRe Agreement
26th Sep 20127:00 amRNSManufacturing Agreement Update
29th Aug 20127:00 amRNSHalf Yearly Report
24th Aug 20124:40 pmRNSSecond Price Monitoring Extn
24th Aug 20124:35 pmRNSPrice Monitoring Extension
14th Aug 20127:00 amRNSRe Agreement
25th Jul 20127:00 amRNSManufacturing Partnership
5th Jul 20127:00 amRNSDirectorate Change
11th Jun 20127:00 amRNSAppointment of New Head of Business Development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.